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ABSTRACT 
 
BACKGROUND. 
 
The effectiveness of a well-controlled programme of early detection and treatment of 
prostate cancer can be evaluated in the population of Tyrol, Austria, where such a 
program of early detection and treatment was initiated in 1988 and where Prostate 
Specific Antigen (PSA) testing was offered for free to all men aged 45 to 75 years 
from 1993. 
 
METHODS 
 
Comparison of prostate cancer mortality rates in Tyrol and the rest of Austria was 
accomplished through a generalised additive model. A piecewise linear change point 
Poisson regression model was used to compare mortality rates in Tyrol and the rest 
of Austria.  Standardised mortality ratios were calculated with reference to the 
mortality rates in 1986-90. 
 
FINDINGS 
 
86.6% of eligible men have been tested at least once since 1993. Cancer deaths in 
Tyrol in 2005 were 54% (95% CI (34%, 69%)) lower than expected compared to 
29% (95% CI 22%, 35%) in the rest of Austria. The decreasing trend in prostate 
cancer mortality was significantly greater in Tyrol compared to the Rest of Austria (p 
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= 0.001). A significant migration to lower stage disease occurred and radical 
prostatectomy was associated with low morbidity.  
 
INTERPRETATION 
 
In the Tyrol region where treatment is freely available to all patients, where 
widespread PSA testing and treatment with curative intent occurs, there is a 
reduction in prostate cancer mortality rates which is significantly greater than the 
reduction experienced in the rest of Austria. This reduction in prostate cancer 
mortality is most likely to be due to early detection, consequent down-staging and 
effective treatment of prostate cancer. 
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INTRODUCTION 
 
Since prostate-specific antigen (PSA) testing for prostate cancer became available, 
both incidence and mortality rates have changed profoundly; between 1989 and 
2002, the age- standardized incidence rate of prostate cancer in the United States 
increased by 21.3 % 1. Prostate cancer is now the most frequently diagnosed non-
cutaneous cancer in Europe and in the United States2. Widespread implementation of 
prostate cancer screening in the United States has led to stage migration with more 
cancers being detected at a lower stage. There has been a 75% reduction reported 
in the proportion of cases presenting with metastatic disease at diagnosis and a 
corresponding 32.5% decrease in the age-adjusted mortality rate from 1993 to 2003 
3,4.  
 
Randomized, controlled trials evaluating the efficacy of PSA and digital rectal 
screening in reducing prostate cancer mortality are underway,5,6,7 but the results will 
not be available for several years. Furthermore, the randomized design of these trials 
may be compromised if non-adherence to the assigned intervention group is 
extensive i.e. widespread contamination of the control group due to members 
seeking PSA testing. 8 The consequences on the statistical power of these trials could 
be considerable 9. 
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It is essential to separate the question of efficacy of screening from the effectiveness 
of a well-controlled screening and treatment programme. The present study reports 
the incidence and mortality rates of prostate cancer in the Federal State of Tyrol, 
Austria, where PSA-testing started in 1988 and has been made freely available to the 
population of men 45 to 75 years of age since 1993. Incidence, stage migration and 
mortality rates of the Tyrol study are reported. The issues of diagnoses – how PSA 
can be used intelligently, the value of anatomical radical prostatectomy and the 
problem of over-diagnosis are discussed in regard to the qualitative effects of 
prostate cancer screening. PSA testing was not available free of charge in the rest of 
Austria, although it was used, probably evolving in a similar manner to use in many 
western countries. Comparison of mortality rates between Tyrol and the rest of 
Austria allows evaluation of the outcome of this natural experiment. 
 
 
METHODS 
 
Study Design 
 
Since 1988, early prostate cancer detection has been promoted by the Department of 
Urology of the University of Innsbruck, Austria, using both PSA and digital rectal 
examination (DRE) in the diagnostic workup of asymptomatic healthy men. Since 
1993, this early prostate cancer detection program has been carried out in the 
Federal State of Tyrol (one of the nine Federal States of the Republic of Austria) with 
prospective data collection and documentation, as well as with the development of 
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an associated biorepository.  Details of all individual PSA test results and biopsies, 
with a unique identifier for the individual man, are recorded so that the cancer 
registry in Tyrol is able to ascertain which men have had at least one PSA test and 
hence calculate the numbers of men who have not been tested. 
 
Tyrol is an alpine region in Western Austria with, at the 1991 census, 631,410 
inhabitants (324,161 women and 307,249 men) in an area of 12,647 square 
kilometers.  At the same census, the total population of Austria was 7.81 million with 
4.05 million women and 3.76 million men. Tyrol is dominated by the mountains of 
the Central Alps, and the distances to Innsbruck, the capital, where the central health 
care unit is located, are not great (infrequently more than 100 kilometers). This 
geographic situation, as well as the willingness of the general population to 
participate in preventive medical programs, is well suited for a state-wide mass 
screening program with PSA as the first-line screening test for the early detection of 
prostate cancer. 
 
PSA testing was made freely available by the Social Insurance Company of the 
Federal State of Tyrol and the University Hospital of Innsbruck to all men aged 45 to 
75 years who were inhabitants of Tyrol. Of the 307,249 male inhabitants in 1993, 
86,067 were between 45 and 75 years of age. All men in this age range were 
advised and encouraged to undergo PSA testing; the information of advantages and 
disadvantages was distributed to all Tyrolean men by press, radio, and television. All 
these releases were approved by the review board of the prostate center at the 
department of Urology, University of Innsbruck.  
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The screening demonstration project was performed in collaboration with general 
practitioners, medical examiners, urologists, medical laboratories, and the Tyrol Blood 
Bank of the Red Cross. The study protocol was approved by the review board of the 
prostate center at the Department of Urology, University of Innsbruck. Informed 
consent was obtained from all volunteers participating in the program. All co-workers 
were fully informed of the guidelines for withdrawal, storage, and shipping of the 
blood samples. PSA was assessed immediately on arrival of the blood or serum 
sample. All volunteers and/or referring physicians were informed about the results in 
writing. In the case of elevated PSA levels, the volunteers were invited to undergo 
additional urologic evaluations at no cost, and the men with normal PSA levels were 
invited to have a repeated PSA test 6 or 12 months later. At the time of drawing 
blood for PSA measurement, no DRE was performed.  
 
PSA testing was provided free of charge to men between 45 and 75 years old and to 
younger men (40 years) with a family history of prostate cancer. In all laboratories, 
the PSA concentration was assessed using the Abbott IMX assay. 
 
Diagnosis 
 
From September 1993 to September 1995, age-referenced PSA levels10, (40-49 
years: 0-2.5 ng/ml, 50-59 years: 0-3.5 ng/ml, 60-69 years: 0-4.5 ng/ml, 70-79 years: 
0-6.5 ng/ml) in combination with percent free PSA of less than 22%, were used as 
the criteria for recommending biopsy.  Since October 1995, lower  PSA levels11 
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(45(40)-49 years: 0-1.25 ng/ml, 50-59 years: 0-1.75 ng/ml, 60-69 years: 0-2.25 
ng/ml, 70-79 years: 0-3.25 ng/ml), together with percent free PSA levels of less than 
18% were used.  In March 1996, an artificial neural network was constructed, using 
total PSA, free PSA , age, DRE and TRUS variables. Using this neural network the 
probability of having cancer could be estimated. In 2005, the concept of PSA-
Velocity12 was incorporated in the diagnostic workup to further enhance the 
specificity of the program (fig.1). 
 
All men who met the above-mentioned biopsy criteria, were invited to undergo 
additional urologic evaluation, including DRE and trans-rectal ultrasound-guided 
biopsies of the prostate. Urologists performed the DRE and transrectal ultrasound 
examinations. Sextant biopsies were initially made using ultrasound guidance with an 
automatic biopsy gun; since 1995, 10 systematic biopsies have been performed, and 
since 1998 additional contrast enhanced color Doppler-targeted biopsies have been 
performed by specialized uroradiologists13 (fig. 2). 
 
Treatment of men with prostate cancer 
 
In men presenting with a clinically localized tumor (clinical T1 and T2 lesions), 
surgical removal of the prostate was recommended. In 1988, anatomical radical 
prostatectomy14 was introduced into the therapeutic concept for localized prostate 
cancer  
 
Patients with a clinical stage T3 lesion were treated with external beam radiotherapy 
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alone. Since 2001, androgen-deprivation therapy was used in combination with 
external beam radiation therapy (70.2 Gy, single fraction 1.8 Gy, four-field 
technique).  Patients with metastatic disease were treated with androgen deprivation 
therapy.  
 
The Austrian Social Insurance System as well as the establishment of a prostate 
center at the Department of Urology ensured that every man diagnosed with prostate 
cancer has access to medical care of the highest quality available in both diagnosis 
and treatment free of charge. 
 
Clinical follow up 
 
All surgically treated patients had a routine follow-up by the treating physician. 1517 
patients (91.2%) had a follow-up of at least one year and were specifically 
questioned about their urinary continence and any complications of treatment by an 
independent investigator. Since 2000 the potency status of 512 men who were 
potent prior to the operation and younger than 65 years was also assessed by an 
independent investigator. Continence was defined as no need for protective pads, 
potency was defined as the ability of having intercourse 2 years after surgery with or 
without PDE5 – Inhibitors. 
 
Cancer Incidence and Mortality Data 
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Population-based data on cancer incidence have been available from the Tyrol 
Cancer Registry, since 1988, and also from the Austrian National Cancer Registry. 
Cancer mortality data have been available, independently, from the Austrian Central 
Statistics Office since 1970. Underlying cause of death was attributed from the death 
certificates of all deaths in Austria by the Central Statistical Office in Vienna, where 
they were unaware of the study being performed in Tyrol.  Annual numbers of cases 
and population estimates are available in five-year age categories. PSA tests were 
available at no charge for men aged 45 to 75 years, although PSA testing was used 
among men in other age groups.  Men who were 40 to 44 years of age in 1993 were 
eligible for screening during the follow-up interval of this study.  
 
During the five year study period, it was assumed that PSA screening could affect 
death rates in the age group beyond screening age range (75 to 79); therefore, 
truncated mortality rates were considered to age 79. Incidence and mortality rates 
for the age range of 40 to 79 years of age were calculated, employing the World 
Standard Population as reference15. 
 
The principal hypotheses to be tested can be expressed as follows: (i) do prostate 
cancer mortality rates in Tyrol decrease from 1993; (ii) do trends in prostate cancer 
mortality rates in Tyrol differ from those in the rest of Austria from 1993 onwards. 
Trends in the mortality rates, for age group, i, and year, y, in Tyrol and the rest of 
Austria were compared within a Poisson regression model.  
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This is a ”change-point” model in which the term ( )1993≥yI  is an indicator which 
permits there to be a different slope from 1993 onwards compared to before 1993.  
The parameter ( i0β ) gives the estimated log mortality rate in the rest of Austria in 
1993 for age group i, and 3β  represents the difference from this value in Tyrol. A 
priori, no difference is anticipated in any age group.  The slope of the relationship 
between log mortality rates and year is given by 1β  in the rest of Austria and 41 ββ +  
in Tyrol; thus 4β  represents the difference in slopes, prior to 1993.  The parameter 
( 2β ) gives an estimate of any change in slope from 1993 onwards compared to 1992 
and before in the rest of Austria.  If there is no change then the estimated value will 
be about zero, if there have been treatment advances then a negative estimate 
would be expected. In the Tyrol the change in the slope from 1993 onwards is given 
by 52 ββ + .  Thus 5β  is the crucial parameter in the analysis as it measures the 
different slope in the Tyrol compared to the rest of Austria from 1993 onwards.  The 
goodness of fit of the model was established on the basis of residual plots and 
hypothesis tests were based on changes in the deviance16.  In particular, interaction 
tests were used to test if the parameters 51 ,, ββ K  depended upon age group.  These 
interactions tests are secondary hypotheses and the effects are only included in the 
final model if significant at the 1% level.   
 
A possible criticism of this analysis is that it assumes a change point model with 
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linear trends for year.  As there is a much longer follow up relative to our previous 
analysis we relax this assumption using a generalised additive model17 where the 
linear trends are replaced by smooth splines.  
 
( ) ( )( )19931993)log( 2310 −++−+= yTyrolsTyrolysrate iiy ββ  
 
In this model ( )1s  represents the trend in the rates in the rest of Austria, while ( )2s  
represents the trend in Tyrol.  All statistical analysis was carried out using Splus 
7.018. 
 
As previously reported19, the estimated benefit of the mass screening program was 
calculated by comparing the observed and expected numbers of prostate cancer 
deaths in Tyrol and by comparing the prostate cancer mortality trends in Tyrol with 
the rest of Austria.  The expected numbers of deaths for each year in Tyrol were 
calculated using the age specific averages of the rates from 1986 to 1990 as the 
reference.  This calculation was carried out for men aged 40-79 and for men aged 
80+. 
 
 
RESULTS 
 
During 1993, when the Tyrol Prostate Cancer Demonstration Project was formally 
launched, 11.0 % of Tyrolean men in the age range of 45 to 75 years had undergone 
PSA screening, and 86.6% of eligible men have been tested at least once during the 
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study period.  From 1988 to 2005, 454,356 PSA measurements were performed in all 
laboratories in the county of Tyrol (table 1). About 85% of all volunteers who, 
according to reference levels used at the time of their test, had an elevated PSA 
level, consented to additional evaluation, including DRE, transrectal ultrasonography 
(TRUS), and needle biopsy of the prostate.  
 
From 1993 to 2005, 7074 TRUS-guided needle biopsies were performed at the 
Innsbruck University Hospital, and prostate cancer was detected in 24% of men with 
a PSA between 2 and 4 ng/ml and 40.2% with a PSA between 4 and 10 ng/ml. The 
morbidity associated with TRUS-guided biopsy was low; major complications were 
seen in fewer than 1% of patients, and 0.5% of patients required hospitalization, 
most commonly for fever.  Among patients diagnosed with T1,T2 disease, 89.3% 
were treated with anatomical radical prostatectomy, 5.7% were treated with 
brachytherapy and 4.7% were treated with external beam radiotherapy; 0.3% of 
patients were managed with a watchful waiting protocol. 
 
The great majority of radical prostatectomies were performed at the Department of 
Urology of the University of Innsbruck, Austria.  Between 1988 and 2005, 1765 
radical prostatectomies were performed mostly by two surgeons (G.B., W.H.). Radical 
prostatectomy was associated with a low morbidity rate; the 30-day mortality was 
zero, and none of the patients suffered a ureteral injury. The rectal injury rate 
decreased from 0.6% before the year 2000 to 0.1% thereafter. Of the patients, 
0.7% had postoperative bleeding requiring intervention. One year after surgery, 
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95.1% of men had recovered urinary continence (no pads) and erectile potency was 
preserved in 78.9% of men younger than 65 years of age (table 2). 
 
The incidence rate of prostate cancer in men aged 40 to 79 years in Tyrol increased 
from 1988 until 1999/2000 and has remained essentially constant since. In the Tyrol 
the incidence rate of organ-confined disease (clinical stage T1 – T2, M0) increased 
from 1988 until 2000 when the rate leveled off.  In the rest of Austria the incidence 
rate for T1-T2, M0 prostate cancer, which was lower than that in the Tyrol from 
1990, has increased gradually and in 2003 was at the same level as Tyrol (fig 3).  
The incidence of metastatic prostate cancer (M1) was lower in the Tyrol, especially 
since about 1995/6, but there is now evidence that the rates are converging (fig 3). 
 
The age standardised rates (World Standard Population weights for ages 40-79) and 
fitted values of the additive model are shown in figure 4 (a) with those from the 
piecewise linear model in figure 4(b). In both cases there is evidence of a good 
agreement between the model and the observed age standardised rates.  The 
deviance test of the more restrictive piecewise linear change point model against the 
additive model yields a non significant change of deviance of 2.95 on 4.0 degrees of 
freedom suggesting that the simpler piecewise linear model is an adequate 
description of the trends.  Of note from the additive model, figure 4(a), is that the 
general trend of the rates in the rest of Austria is of a smooth curve peaking around 
1990.  Prior to 1990 there was a similar trend in Tyrol as in the rest of Austria but in 
the last 10 years, especially the rate of decrease of the mortality rates has been 
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much steeper in Tyrol compared to the rest of Austria. The predicted line in Tyrol is 
lower than that for the rest of Austria from 1995 onwards.  
 
Using the piecewise linear model, figure 4(b), there was no evidence of any 
interactions between age group and the effects of the comparison between Tyrol and 
the rest of Austria – Intercept in Tyrol in 1993, 3β , p=0.29; slope in Tyrol prior to 
1993, 4β , p=0.50; slope in Tyrol after 1993, 5β , p=0.35.  There was some evidence 
that the overall trends in the age groups were not parallel – trend prior to 1993, 1β , 
p=0.04; trend after 1993, 2β , p=0.01.  These interactions are not important as 
regards the main comparison between Tyrol and the rest of Austria and are ignored 
in the remainder. The interactions manifest themselves with slightly weaker trends 
over time among those aged 40-54 (where there are comparatively few deaths), 
compared with those aged 55-79.  
 
There is no evidence that the trends in the rates in Tyrol and the rest of Austria 
before 1993 are significantly different (X2 = 0.42, 1 degrees of freedom, p=0.52).  In 
Tyrol the log mortality rates increased at a rate of 0.0093 (standard error 0.0043) 
per year while in the rest of Austria the increase was 0.0065 (s.e. 0.0011) per year.  
Furthermore, in 1993, there was no evidence of any difference between the 
estimated rates in the two regions (p=0.16). From 1993 onwards there is strong 
evidence of a decrease in mortality in Tyrol (X2 = 39.2, 1 degree of freedom, p < 
0.0001) where the log mortality rates have decreased at a rate of 0.0763 (s.e. 
0.0122) per year, corresponding to a yearly reduction in mortality rate of 7.3% (95% 
CI 5.1%, 9.5%).  In the rest of Austria there is also a significant decrease in the log 
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mortality rates of 0.0324 (s.e. 0.0032) per year, corresponding to a decrease of 
3.2% per year (95% CI 2.6%, 3.8%) in the mortality rate.  There is very strong 
evidence that the decrease from 1993 in Tyrol is significantly greater than the 
decrease in the rest of Austria (X2 = 12.3, 1 degree of freedom, p= 0.001).  
 
Although, there were no statistically significant differences between Tyrol and the 
rest of Austria prior to 1993 the fitted value in Tyrol in 1993 is slightly higher than in 
the rest of Austria (see figure 4), and this may have some implications for the 
change in the slope.  To investigate the effect of this we constrain the line before 
1993 to be exactly the same in Tyrol as in the rest of Austria.  This is achieved by 
setting 3β  and 4β both equal to zero in the model. Now the rate of increase in the 
log mortality rates is 0.0067 (s.e. 0.0011) per year which is very similar to that for 
the rest of Austria above as Tyrol is a small part of Austria. In the rest of Austria the 
rate of decrease from 1993 onwards is 0.0332 (s.e. 0.0031) per year while in the 
Tyrol it is 0.0651 (s.e. 0.0072) per year. The test statistic for the comparison of the 
slopes from 1993 onwards is X2 = 21.08 (p<0.0001).  
 
The standardized mortality ratios in Table 3 demonstrate a reduction in the number 
of prostate cancer deaths, among men aged 40-79, relative to those expected on the 
basis of the age specific rates in the immediate pre-screening years (1986-90).  In 
2005 in Tyrol there was a 54% (95% Confidence Interval, 34%, 69%) reduction 
compared to 29% (95% CI, 22%, 35%) in the rest of Austria.  Among men aged 80 
or over in the Tyrol, there was no evidence of an increase in prostate cancer deaths 
from 1991 onwards.  Indeed, there were 36% (95% CI, 10%, 56%) fewer prostate 
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cancer deaths than expected in 2005.  In the rest of Austria there was evidence of 
an increase in the number of prostate cancer deaths among men 80 or over from 
1995 to 2003 associated with the increase in the number of men in this age group. 
 
In the period of 1996 to 2005, there were 567 expected (based on pretesting rates 
from 1980 to 1990), but only 347 observed prostate cancer deaths (reduction: 
38.8%).  As shown by the expected and observed deaths rates in men older than 80 
years, there was a smaller, yet still substantial, decrease in the prostate cancer 
mortality rate (period 2002 to 2005, men older than 80: 187 expected deaths, 134 
observed deaths) (reduction:28.4%). 
 
 
DISCUSSION 
 
This report is based on a demonstration project conducted in the population of Tyrol, 
Austria, where PSA testing has been offered to men free of charge since 1993.  Even 
without a system of invitation and re invitation, more than 4 men out of 5 aged 45 to 
74 years underwent at least one PSA test for screening in the years 1993 to 2005  
(table 1). 
 
During the past decade, there has been a dramatic stage migration for newly 
diagnosed prostate cancer. Currently, 80 % of men are diagnosed with prostate 
cancer while it is pathologically organ confined, compared to only 20% to 30 % in 
the “pre-PSA era” 20. In the SEER program, the rate of distant disease fell by 52 % 
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between 1990 and 1994 21.  
 
A similar favorable stage migration is documented in the Tyrol Project and can almost 
certainly be attributed, at least in part, to the widespread acceptance of PSA-based 
prostate cancer screening. Several studies have clearly demonstrated that cancers 
detected because of a PSA elevation are more likely to be organ confined than those 
detected because of an abnormal digital rectal examination 20-26. 
 
Prostate cancer incidence data from Tyrol show that the age-standardized rate for 
metastatic cancer decreased from 5.2 to 2.1 per 100,000 and for advanced cancer 
(UICC stage IV) from 7.9 to 3.7 per 100,000 from the period 1988-1992 to 1998-
2002. This is consistent with a population-based, case-control study showing that 
among asymptomatic men, the frequency of PSA-testing was significantly lower 
among men with metastatic prostate cancer 27. 
 
Since PSA thresholds lower than the traditional 4 ng/ml for recommending a prostate 
biopsy were adopted, a highly significant increase in the proportion of patients with 
pathologically organ-confined disease has been observed:  this rose from 23.7% in 
1993 to 78.7% in 2005. Similar results were reported in a 12-year PSA-based 
screening study when the pathological features of prostate cancers detected were 
compared from 3 consecutive time intervals 28. 
 
Screening for prostate cancer, viewed as the first step in patient management would 
not lead to an improved outcome if the cancers detected were either clinically 
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insignificant, already incurable or if the available treatment options were ineffective. 
For prostate cancer this has been shown not to be the case. The Scandinavian 
Prostate Cancer Group Study reported on outcomes of 347 men with early, non-
screen-detected prostate cancer randomized to radical prostatectomy, compared to 
348 men randomized to watchful waiting29. The risk of overall mortality, cancer-
specific mortality, distant metastasis, and local progression were all significantly 
lower in the patients treated with radical prostatectomy after 8 years of follow-up. 
After 10 years, there also was a significant improvement in overall survival in patients 
treated with radical prostatectomy29. 
 
It is likely that treatment with the intention to cure for early prostate cancer has 
contributed to the decreases in prostate cancer mortality observed in countries such 
as the United States, where treatment with radical prostatectomy and radiation 
therapy is widely practiced. Extrapolating these findings to a population of men who 
undergo screening, the removal of small tumors should improve survival by detecting 
the life-threatening tumors earlier. In the Tyrol screening project, the treatment of 
patients with clinical stage T1 or T2 lesions was radical prostatectomy in 89.3 %, 
performed largely in a high-volume tertiary referral center by experienced surgeons 
and was associated with low morbidity30 (95.1 % urinary continence (no pads) after 
12 months; 78.9% preservation of erectile potency in men < 65 years of age). The 
probability of clinical cancer progression following radical prostatectomy in patients 
with low PSA levels (<4 ng/ml), a low positive surgical margin rate (4.2 %), and a 
low biochemical recurrence rate (5.7%) is low. Therefore, in the long term, patients 
with early-stage prostate cancer is detected through PSA screening who are treated 
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effectively should be expected to have a lower prostate cancer mortality rate.  
 
The controversy surrounding screening for prostate cancer with PSA revolves around 
three key issues. Does PSA identify clinically significant prostate cancer in the 
majority of cases?  Does aggressive intervention with surgery or radiation alter the 
outcome in men diagnosed with clinically significant disease?  Does diagnosis and 
treatment seriously impinge of quality of life? 
 
The estimates of prostate cancer “overdiagnosis” (30 % to 50 %) have been 
exaggerated in the literature. 31,32  This may be due in part by the fact that much of 
the data have been derived from older men, in whom overdiagnosis is a greater 
concern because of their limited life expectancy. In younger men, who are most 
likely to benefit from early diagnosis and treatment, the criteria for calling 
overdiagnosis are much less frequently met (~15 %)32 . Nevertheless, a recent study 
has shown that even men over 65 years of age have a mortality benefit from 
treatment with radical prostatectomy or radiation therapy33. In the Tyrol study,  in 
which the mean age of screened men was less than 65 years, the estimate of 
overdiagnosis according to the criteria of Epstein 34 was 8,7 % 35. 
 
Using the pathology criteria in the prostatectomy specimen for overdiagnosis of 
pathologic stage T2a, Gleason<7, overdiagnosis in the Tyrol Project was 19.7% in 
the PSA range of 2 ng/ml  to 4 ng/ml and 17.6% in the PSA range of 2 ng/ml to 10 
ng/ml34. In another screening study, using the Ohori criteria for unimportant 
disease25, fewer than 10% of men underwent treatment for “overdiagnosed” prostate 
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cancer36. 
 
Although reduction in prostate cancer mortality rates are important, it is also 
necessary to consider the effects of prostate cancer screening and treatment on 
patient quality of life. Potential gains in survival could be more than offset by 
decrements in quality of life that may result from diagnosis and treatment 37. 
Ecological data suggest that 10 % to 30 % of the geographic variation in mortality 
rates may relate to variations in access to medical care 38. A key feature of this study 
setting is that patients in Tyrol have equal access to all therapeutic resources 
(surgery, radiotherapy and hormonal therapy) and that diagnosis and therapy are 
free of charge for everyone.  
 
Population-based reductions in prostate cancer mortality rates may be the only way 
to assess the impact of prostate cancer screening. Although androgen-deprivation 
therapy can slow the progression of prostate cancer, as a curative treatment for 
advanced disease is not available yet, any reduction in mortality is likely attributable, 
at least in part, to programs that detect prostate cancer at an early stage and 
prevent the tumor acquiring the lethal phenotype. Since PSA screening was widely 
implemented in 1990, prostate cancer mortality in the United States has decreased 
dramatically.  The prostate cancer mortality rate has decreased by an average of 
2.4% yearly from 1993 to 20033.  Between 1993 and 2002, the truncated (40-79) 
age standardised prostate cancer mortality rate in the United States has decreased 
by an average of 4.7% per year.  In Austria, excluding Tyrol, the decline was 3.2% 
per year while in the Tyrol it was 7.3%.  The dramatic shift of stage in the PSA era 
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followed by effective therapy should translate into a decrease of mortality. 
 
Data from the Tyrol have been presented here using the same approach as in the 
previous report19 for the purpose of maintaining longitudinal transparency of our 
study findings. These findings continue to be consistent with the notion that making 
PSA testing freely available, and its wide acceptance by men in the population, is 
associated with a reduction in prostate cancer mortality in a region where potentially 
curative prostate cancer treatment services are available free of charge to all 
patients. 
 
Although it is not possible from the available data to separate the individual 
contributions of PSA testing and curative treatment to the favorable outcomes, the 
more rapid accelerated decline in mortality rates in Tyrol compared to the rest of 
Austria is unlikely to be artefactual. The delay between early detection and radical 
treatment beginning in 1988 (accelerating in 1993) and the decline in mortality in the 
targeted age range which started in 1996, is comparable with that seen in other 
screening programs with high compliance. It is likely that much of this decline in 
mortality rates is due to earlier detection and successful treatment of prostate 
cancer. However, an important corollary implication of our study is that screening is 
only the first step in the optimal management of prostate cancer patients. 
 
Pending the results of the large randomized clinical trials, there is a great public 
health need to know more details of the potential risks and benefits of PSA testing. 
However, it is likely that, given the penetrance of PSA testing in communities of men, 
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even null findings from these randomised trials will not deter future PSA testing 
rates37. 
 
The study group described here is a well-defined population of Tyrol, where detailed 
knowledge of PSA testing rates and information on therapy offered to the population 
exist.  Of course, the design of our study cannot overcome the problems inherent in 
non-randomized studies, but it can provide useful information on the potential 
benefits of early detection in a real-life setting. 
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Table 1 
 
 
Annual Uptake rates of PSA Testing in Tyrol in Age Group 45-74 Years 
 
 
 
 
 
Men with 
PSA 
screening 
test 
 
Male 
Population 
 
Testing 
rate 
 
Cumulative 
Testing rate 
 
 
1993 
 
9,474 
 
86,067 
 
11.0% 
 
11.0% 
 
1994 
 
14,147 
 
88,342 
 
16.0% 
 
23.3% 
 
1995 
 
20,309 
 
90,153 
 
22.5% 
 
34.6% 
 
1996 
 
23,839 
 
91,497 
 
26.1% 
 
44.1% 
 
1997 
 
26,796 
 
92,607 
 
28.9% 
 
51.0% 
 
1998 
 
30,228 
 
93,719 
 
32.3% 
 
56.8% 
 
1999 
 
36,366 
 
95,000 
 
38.3% 
 
63.3% 
 
2000 
 
41,860 
 
96,692 
 
43.3% 
 
70.1% 
 
2001 
 
44,400 
 
98,638 
 
45.0% 
 
75.1% 
 
2002 50,370 100,740 50.0% 80.2% 
 
2003 51,658        102,904 50.2% 84.0% 
 
2004 
 
52,503 
 
       105,216 
 
49.9% 
 
86.1% 
 
2005 
 
46,591 
 
       107,600 
 
43.3% 
 
86.6% 
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Table 2 
 
 
RADICAL PROSTATECTOMY: MORBIDITY AND MORTALITY, 1988 - 2004 : 
1.663 patients 
 
Mortality (30 days) 
 
n= 1663 
 
0% 
 
Rectal injury 
 
n= 1663 
 
0.6%, since 2000:  0.1% 
 
 
Ureteral injury 
 
n= 1663 0.0% 
 
 
Bleedings requiring intervention 
 
n= 1663 0.7% 
 
 
Continence (no pads) 
  (12 months postop.) 
 
  (3 months postop.) 
 
n= 1517 
 
 
 
 
 
95.1% 
 
80.6% 
 
Potency  < 65 years, since 2000 
 
n= 512 78.9% 
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Table 3 
 
Observed and Expected numbers of Prostate cancer deaths in Tyrol and 
the rest of Austria for men aged 40-79 and 80+.[Expected values are 
based on the application of age-specific rates from 1986-1990 to the 
population]. 
 
Aged 40-79 Tyrol Rest of Austria
Year Deaths
Expected 
Deaths SMR 
Lower 
Limit
Upper 
Limit Deaths
Expected 
Deaths SMR 
Lower 
Limit
Upper 
Limit
1991 50 44.1 113.4 84.1 149.5 606 544.5 111.3 102.6 120.5
1992 44 43.6 100.8 73.3 135.4 546 538.6 101.4 93.1 110.3
1993 52 43.2 120.4 89.9 157.9 554 534.7 103.6 95.2 112.6
1994 42 43.4 96.8 69.8 130.9 489 536.8 91.1 83.2 99.5
1995 45 44.8 100.4 73.2 134.4 516 552.3 93.4 85.5 101.8
1996 37 47.1 78.6 55.3 108.3 543 580.2 93.6 85.9 101.8
1997 33 49.7 66.4 45.7 93.3 559 611.9 91.4 83.9 99.3
1998 30 52.3 57.4 38.7 81.9 575 641.4 89.6 82.5 97.3
1999 37 54.8 67.6 47.6 93.1 602 664.6 90.6 83.5 98.1
2000 32 56.8 56.4 38.6 79.6 606 680.8 89.0 82.1 96.4
2001 44 57.5 76.5 55.6 102.7 571 679.1 84.1 77.3 91.3
2002 44 59.2 74.3 54.0 99.7 578 689.2 83.9 77.2 91.0
2003 32 61.2 52.3 35.8 73.8 537 694.0 77.4 71.0 84.2
2004 28 63.3 44.2 29.4 63.9 549 714.6 76.8 70.5 83.5
2005 30 65.3 45.9 31.0 65.6 517 730.0 70.8 64.9 77.2
Aged 80+ Tyrol Rest of Austria
Year Deaths
Expected 
Deaths SMR 
Lower 
Limit
Upper 
Limit Deaths
Expected 
Deaths SMR 
Lower 
Limit
Upper 
Limit
1991 46 39.7 115.8 84.8 154.5 504 451.7 111.6 102.0 121.8
1992 47 41.6 113.0 83.0 150.2 502 465.0 107.9 98.7 117.8
1993 44 43.3 101.7 73.9 136.6 527 479.7 109.9 100.7 119.7
1994 53 44.6 118.7 88.9 155.3 504 491.5 102.5 93.8 111.9
1995 48 44.9 106.9 78.8 141.7 593 494.6 119.9 110.4 130.0
1996 54 44.1 122.6 92.1 159.9 535 484.4 110.4 101.3 120.2
1997 55 43.2 127.3 95.9 165.7 537 471.1 114.0 104.6 124.1
1998 30 42.4 70.8 47.7 101.0 504 459.7 109.6 100.3 119.6
1999 42 42.7 98.5 71.0 133.1 541 457.5 118.2 108.5 128.6
2000 47 43.7 107.4 78.9 142.9 544 472.6 115.1 105.6 125.2
2001 41 42.7 95.9 68.8 130.1 528 466.8 113.1 103.7 123.2
2002 35 44.0 79.5 55.3 110.5 481 486.5 98.9 90.2 108.1
2003 36 45.5 79.0 55.4 109.4 553 489.8 112.9 103.7 122.7
2004 31 47.7 65.0 44.1 92.2 531 527.4 100.7 92.3 109.6
2005 32 49.9 64.1 43.8 90.5 518 556.4 93.1 85.2 101.5
95% Confidence
95% Confidence 95% Confidence
95% Confidence
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Legends for figures: 
 
 
Fig. 1: Tyrol Prostate Cancer Demonstration Project: Evolution of 
early detection algorithm. 
 
Fig. 2: Tyrol Prostate Cancer Demonstration Project: Evolution of  
  diagnostic work up. 
 
Fig. 3: Prostate Cancer Incidence Rates per 100,000 by tumour 
stage in the county of Tyrol and the Republic of Austria 
excluding the county of Tyrol 
 
Fig. 4: Prostate Cancer Mortality rates men aged 40-79 in the 
county of Tyrol and in the Republic of Austria excluding the 
county of Tyrol 
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Fig. 1: Tyrol Prostate Cancer Demonstration Project: Evolution of 
early detection algorithm. 
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Fig. 2: Tyrol Prostate Cancer Demonstration Project: Evolution of  
  diagnostic work up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript submitted for publication  31 
 
 
Fig. 3: Prostate Cancer Incidence Rates per 100,000 by tumour 
stage in the county of Tyrol and the Republic of Austria 
excluding the county of Tyrol 
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Figure 4 (a)  Age standardised mortality rates and Predictions from a GAM model – 
separate smoothing trend in Tyrol and Rest of Austria 
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Figure 4 (b)  Age standardised mortality rates and Predictions based upon linear 
change point model with Age interactions 
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